CA2190867C - Procedes pour l'absorption renale reduite de fragments d'anticorps - Google Patents

Procedes pour l'absorption renale reduite de fragments d'anticorps Download PDF

Info

Publication number
CA2190867C
CA2190867C CA002190867A CA2190867A CA2190867C CA 2190867 C CA2190867 C CA 2190867C CA 002190867 A CA002190867 A CA 002190867A CA 2190867 A CA2190867 A CA 2190867A CA 2190867 C CA2190867 C CA 2190867C
Authority
CA
Canada
Prior art keywords
lysine
poly
radiolabelled
kidney
molecular weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002190867A
Other languages
English (en)
Other versions
CA2190867A1 (fr
Inventor
Thomas M. Behr
David M. Goldenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Center for Molecular Medicine and Immunology
Original Assignee
Center for Molecular Medicine and Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Center for Molecular Medicine and Immunology filed Critical Center for Molecular Medicine and Immunology
Publication of CA2190867A1 publication Critical patent/CA2190867A1/fr
Application granted granted Critical
Publication of CA2190867C publication Critical patent/CA2190867C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6895—Rescue therapy; Agonist-antagonist; Antidotes; Targeted rescue or protection, e.g. by folic acid-folinic acid or conjugated to antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

On réduit chez des patients l'absorption rénale de conjugués de fragments d'anticorps en leur administrant un ou plusieurs composés choisis dans le groupe comprenant D-lysine, poly-D-lysine ou poly-L-lysine, ou des sels ou des dérivés carboxyle de ceux-ci, acceptables sur le plan pharmacologique.
CA002190867A 1995-03-21 1996-03-20 Procedes pour l'absorption renale reduite de fragments d'anticorps Expired - Fee Related CA2190867C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/407,899 US5843894A (en) 1995-03-21 1995-03-21 Methods for reduced renal uptake of antibody fragments
US08/407,899 1995-03-21
PCT/US1996/003308 WO1996029087A1 (fr) 1995-03-21 1996-03-20 Procedes pour l'absorption renale reduite de fragments d'anticorps

Publications (2)

Publication Number Publication Date
CA2190867A1 CA2190867A1 (fr) 1996-09-26
CA2190867C true CA2190867C (fr) 2009-06-02

Family

ID=23614010

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002190867A Expired - Fee Related CA2190867C (fr) 1995-03-21 1996-03-20 Procedes pour l'absorption renale reduite de fragments d'anticorps

Country Status (9)

Country Link
US (4) US5843894A (fr)
EP (1) EP0767673B1 (fr)
JP (1) JPH10505866A (fr)
AT (1) ATE254469T1 (fr)
CA (1) CA2190867C (fr)
DE (1) DE69630761T2 (fr)
ES (1) ES2211951T3 (fr)
IL (1) IL117564A (fr)
WO (1) WO1996029087A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843894A (en) * 1995-03-21 1998-12-01 Center For Molecular Medicine And Immunology Methods for reduced renal uptake of antibody fragments
EP1187637A2 (fr) * 1999-06-07 2002-03-20 Center For Molecular Medicine And Immunology Emetteurs alpha ou beta fixes a des fragments, utilises en radiotherapie
AU6275800A (en) * 1999-07-16 2001-02-05 Mallinckrodt, Inc. Inhibition of renal uptake of molecules that are potentially damaging for the kidney
EP1862172A1 (fr) * 2006-05-31 2007-12-05 BioSynthema Inc. Combinaison d'une solution d'acides aminés et de gélatine pour l'inhibition de l'absorption rénale
WO2013106824A1 (fr) * 2012-01-13 2013-07-18 Board Of Regents, The University Of Texas System Agents ciblant les récepteurs des éphrines

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283342A (en) * 1992-06-09 1994-02-01 Neorx Corporation Biotinylated small molecules
US4701521A (en) * 1978-07-17 1987-10-20 The Trustees Of Boston University Method of effecting cellular uptake of molecules
US5595734A (en) * 1988-04-06 1997-01-21 Alfacell Corporation Compositions comprising ONCONASE (tm) and lovastatin
ATE136224T1 (de) * 1989-09-29 1996-04-15 Neorx Corp Reduktion der nichtzielspezifischen retention von immunokonjugaten und ihren metaboliten
US5225180A (en) * 1991-09-10 1993-07-06 Diatech, Inc. Technetium-99m labeled somatostatin-derived peptides for imaging
US5843894A (en) * 1995-03-21 1998-12-01 Center For Molecular Medicine And Immunology Methods for reduced renal uptake of antibody fragments
US5840296A (en) * 1997-10-15 1998-11-24 Raines; Ronald T. Engineered cytotoxic ribonuclease A

Also Published As

Publication number Publication date
IL117564A0 (en) 1996-07-23
US20060182683A1 (en) 2006-08-17
US20020111300A1 (en) 2002-08-15
CA2190867A1 (fr) 1996-09-26
ATE254469T1 (de) 2003-12-15
US20030203836A1 (en) 2003-10-30
IL117564A (en) 2005-03-20
DE69630761T2 (de) 2004-09-23
AU700346B2 (en) 1999-01-07
AU5361696A (en) 1996-10-08
EP0767673A1 (fr) 1997-04-16
EP0767673B1 (fr) 2003-11-19
EP0767673A4 (fr) 1999-08-04
JPH10505866A (ja) 1998-06-09
DE69630761D1 (de) 2003-12-24
WO1996029087A1 (fr) 1996-09-26
ES2211951T3 (es) 2004-07-16
US5843894A (en) 1998-12-01

Similar Documents

Publication Publication Date Title
Behr et al. Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion
Behr et al. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives
DeNardo et al. Treatment of B cell malignancies with 131I LYM‐1 monoclonal antibodies
Chakrabarti et al. Prevention of radiolysis of monoclonal antibody during labeling
CN1185252C (zh) 生长激素释放抑制因子肽类
CA2405469A1 (fr) Composes a base de peptides
JPH10508832A (ja) 腎臓による取り込みが減少する修飾放射性抗体フラグメント
JPH06510539A (ja) 放射性標識ペプチドおよびタンパク質の自己放射線分解を防止する安定剤
JPH08502075A (ja) 標識された単球走化性因子タンパク質材料およびその医学的使用
JPH09504526A (ja) 感染または炎症の病巣部位をイメージするための標識化走化性ペプチド
Jones et al. Therapeutic application of a radiolabelled monoclonal antibody in nude mice xenografted with human neuroblastoma: tumoricidal effects and distribution studies
JP2000515847A (ja) ペプチド放射性医薬品用途
CA2190867C (fr) Procedes pour l'absorption renale reduite de fragments d'anticorps
CA2379696C (fr) Inhibition de l'absorption renale de molecules pouvant potentiellement endommager les reins
Chen et al. In vivo examination of 188Re (I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer
Behr et al. Improved prospects for cancer therapy with radiolabeled antibody fragments and peptides?
CA2066031C (fr) Methodes de reduction de la retention non recherchee d'immunoconjugues et metabolites obtenus
AU700346C (en) Methods for reduced renal uptake of antibody fragments
Carrasquillo et al. Aminosyn II effectively blocks renal uptake of 18F-labeled anti-tac disulfide-stabilized Fv
WO2020238800A1 (fr) Produits radiopharmaceutiques ciblés pour des tumeurs, et polythérapie pour la radiothérapie ciblée de celles-ci et immunothérapie sous la direction d'images
JP2006508044A (ja) 腫瘍の治療方法
del Rosario et al. Biotinylated iodo-polylysine for pretargeted radiation delivery
Epenetos et al. Antibody-guided irradiation of hepatic metastases using intrahepatically administered radiolabelled anti-CEA antibodies with simultaneous and reversible hepatic blood flow stasis using biodegradable starch microspheres
NZ224803A (en) A composition comprising a hepatic blocking agent and an immunoconjugate
EP0700930B1 (fr) Peptides à affinité pour des tumeurs et composés radioactifs diagnostiques et thérapeutiques les contenant

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130320